We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Analytical Cannabis Logo
Home > Resources > Videos > Content Piece

Formulating the Case for Cannabidiol: Methods and results from an open-label anxiety trial

Published: Apr 27, 2022   

Speaking at the Analytical Cannabis Expo East Online 2021 back in October, Dr. Staci Gruber, Associate Professor of Psychiatry at Harvard Medical School presented the clinical trial results from a full-spectrum cannabidiol (CBD) sublingual product for anxiety.

In this talk, Dr. Gruber will discuss her groundbreaking clinical trial of a full-spectrum cannabidiol (CBD) sublingual product for anxiety. She will describe the path from product selection to implementation of the clinical trial, including legal considerations, a summary of formulation procedures, and an overview of laboratory analyses (e.g., cannabinoid quantification and product safety tests). She will describe the study design which includes the recently completed four-week open-label phase as well as a currently in-progress double-blind phase designed to assess the efficacy of a full spectrum CBD product vs a matched CBD isolate vs placebo. Dr. Gruber will also highlight promising results from the open-label phase, which noted significant reductions in anxiety and related symptomatology over the course of treatment. In addition, she will describe the impact of four weeks of CBD treatment on aspects of cognitive functioning, including executive function and memory. Finally, she will present interesting findings from the clinical trial regarding urinary THC status, which have important public health implications.

  More Information

Stay connected with the latest news in cannabis extraction, science and testing

Get the latest news with the FREE weekly Analytical Cannabis newsletter